focus -WSS

focus

author：explore 2025-10-02 21:07:06 - browse：6741

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： SAMSHA loosens regulations on methadone treatment centers

Wikipedia

WSS

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Covid misinformation case heads to Supreme Court

A rare thyroid diagnosis led to unexpected, all

ARCH Venture Partners is raising $3 billion for a life sciences fund

Ethical issues complicate the benefits of medical crowdfunding

The real point of Kenneth Smith’s execution by nitrogen gas

leisure time

focus

Wikipedia

New air purifier tech could be key to improving indoor air quality

Medicare drug price negotiation’s day in court

What does generative AI mean for health care? We asked experts

Vertigo drug brings hope for rare neuron disorder, Niemann

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The (many) problems with a new study criticizing cancer screening

Wildfire smoke exposes gaps in outdoor worker protections

Even great ERs can’t make up for American health disparities

Apple is now the first public company to be valued at $3 trillion

Medicare drug price negotiation’s day in court

Wikipedia

Crinetics acromegaly drug succeeds in late

What drug price negotiations mean for Medicare Part D

Vertex non

What drug price negotiations mean for Medicare Part D

ALS advocates say criticism of new drugs misses bigger picture

ARCH Venture Partners is raising $3 billion for a life sciences fund

knowledge

Wikipedia

focus

hotspot